Nanovi A/S (Nanovi) is a Danish medical device company specialized in precision marking for better cancer therapy.
Our corporate commitment is to empower healthcare professionals with the best possible tools to support the delivery of image-guided high precision radiation therapy and surgery to benefit cancer patients and to support efficient healthcare.
Our product portfolio comprises unique in-house developed and manufactured liquid fiducial markers for both human and veterinary use:
Bioxmark® is a liquid fiducial marker which enhances target visibility on imaging to enable high precision cancer radiation therapy, including proton beam therapy. In radiation therapy, good target visibility on relevant imaging modalities provides for accurate target delineation and verification of patient setup at the point of treatment, to support high treatment precision and quality.
PetXmark™ is a liquid fiducial marker for use to radiographically mark subcutaneous tissue in dogs and cats and our first veterinary product. PetXmark™ has been evaluated in a clinical trial for use to guide radiotherapy of skin and subcutaneous tumors and is commercialized in the US.
Nanovi’s products are derived from a patented biomaterial platform, co-invented with the Department of Health Technology at the Technical University of Denmark, DTU.